ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-PO360

Vascular Abnormalities in CKD Patients

Session Information

Category: Hypertension and CVD

  • 1402 Hypertension and CVD: Clinical, Outcomes, and Trials

Authors

  • Hojs, Nina, University Clinical Centre Maribor, Maribor, Slovenia
  • Junarta, Joey, St. George''s, University of London, London, United Kingdom
  • Ramphul, Robin, St. George's University Hospitals NHS Foundation Trust, Worthing, United Kingdom
  • Lowe-Jones, Racquel M., St George''s University Hospital, London, United Kingdom
  • Kaski, Juan carlos, SGUL, LONDON, United Kingdom
  • Banerjee, Debasish, St Georges Hospital and St Georges University of London, Wimbledon, lONDON, United Kingdom
Background

CKD patients suffer from excess vascular events. The exact nature of vascular abnormalities and their progression is unknown. The aim of our study was to compare vascular abnormalities and its progression in 3-6 months in different CKD groups and healthy controls.

Methods

A detailed vascular assessment was performed in clinically stable patients (21 CKD stage 2-4, 14 haemodialysis (HD), 22 transplant (TX)) and 21 healthy controls in a quiet, temperature controlled vascular laboratory; at baseline and 3-6 months. Data were analysed with SPSS version 25, P value <0.05 was considered significant.

Results

The carotid intima media thickness (CIMT) differed significantly between all groups at baseline and after 3-6 months. As expected, the lowest values were present in healthy controls and the highest in CKD2-4 and HD patients. Ankle brachial index (ABI) significantly differed between groups at baseline, but not after 3-6 months. Brachial flow mediated dilatation (FMD) didn't differ between groups at baseline or on follow up. Pulse wave velocities (PWV) were significantly different between different groups, with the highest values in HD and CKD2-4 patients and the lowest values in healthy controls.
During 3-6 months CIMT increased significantly only in TX patients. ABI significantly decreased in 3-6 months in the CKD2-4 patients. FMD decreased in 3-6 months in TX patients. PWV didn't change significantly in 3-6 months in all groups.

Conclusion

CKD2-4, HD, TX patients and healthy controls differ significantly in CIMT, ABI and PWV, with the most abnormal values present in HD patients. Progression of cardiovascular disease in this short term follow up was variable, with worsening of FMD and CIMT in TX patients.

 CKD2-4HDTXControlsANOVA
P value
CIMT1 (mm)7.05±1.446.86±1.335.89±0.925.55 ±1.030.000*
CIMT2 (mm)7.42±1.547.08±0.766.13±0.985.723±1.340.001*
CIMT1-CIMT2
P value (pair t-test)
0.5220.1730.010*0.224 
ABI11.18±0.171.39±0.341.28±0.191.20±0.080.013*
ABI21.12±0.181.16±0.121.24±0.131.21±0.110.069
ABI1-ABI2
P value (pair t-test)
0.046*0.7360.2730.427 
FMD1 (%)3.60±2.483.03±2.074.07±4.064.41±2.820.577
FMD2 (%)2.21±1.742.11±1.712.69±2.193.51±2.730.292
FMD1-FMD2
P value (pair t-test)
0.0590.0550.024*0.327 
PWV1 (m/s)10.46±2.5411.88±2.547.88±1.806.98±1.270.000*
PWV2 (m/s)10.26±2.4411.35±2.858.41±2.227.17±1.500.000*
PWV1-PWV2
P value (pair t-test)
0.2590.4220.0670.513